Disclosure: The Iron Verdict may earn commissions from qualifying purchases at no extra cost to you. Learn more ->
Top Picks ->
SupplementsTrainingLongevityArticles & ResearchCalculatorsPeptidesBooks
Home / Articles & Research / GLP-1 Medications

Alcohol And GLP-1 Medications: What The Evidence Shows

Reports that people drink less on these medications turned out to be testable, and somebody tested them. The trial is small and short, which matters — but it is a randomised trial, not an anecdote.

Publication date: 2026-08-09Last updated: 2026-08-09Reading time: 7 minAuthor: The Iron Verdict Research Team

What You'll Learn

The TrialDesign, dose and what it measured.
The ResultEffect on drinking and craving.
The LimitsWhy this is early evidence.
Why It Might HappenGLP-1 receptors beyond the gut.
Practical IssuesAlcohol on a suppressed appetite.
What This Is NotNot an approved treatment.

Table of Contents

  1. What Was Actually Tested
  2. Why This Is Early Evidence, Not A Conclusion
  3. Why It Might Happen At All
  4. Drinking On A GLP-1: Practical Considerations
  5. What This Evidence Is Not
  6. FAQ
  7. Scientific references

What Was Actually Tested

Anecdotal reports of reduced drinking on GLP-1 medications circulated long before anyone ran a controlled test. In 2025 one was published.

Semaglutide reduced drinks per drinking day and cravingRandomised clinical trial
Hendershot CS, et al. — JAMA Psychiatry, 2025;82(4):395–405

48 adults with alcohol use disorder were randomised to low-dose semaglutide (0.25 mg/week escalating to 1.0 mg) or placebo for 9 weeks. Semaglutide significantly reduced drinks per drinking day (β −0.41; 95% CI −0.73 to −0.09; P=.04) and weekly alcohol craving (β −0.39; 95% CI −0.73 to −0.06; P=.01). Small sample, short duration, early evidence.

PubMed PMID: 39937469 ↗

Bottom line: A statistically significant reduction in both drinks per drinking day and weekly craving, in a randomised placebo-controlled design. That is a real signal — in 48 people over nine weeks.

Why This Is Early Evidence, Not A Conclusion

Being fair to the data means naming its limits, and they are substantial:

  • 48 participants. Small trials produce less precise estimates and are more easily overturned.
  • Nine weeks. Nothing here speaks to whether the effect persists.
  • Low doses. Escalation only reached 1.0 mg weekly, below typical weight-management dosing.
  • A specific population. Adults with alcohol use disorder, not a general population of people on GLP-1 therapy for weight.

Larger trials are underway. Until they report, the accurate description is a promising early finding.

Why It Might Happen At All

GLP-1 receptors are not confined to the gut and pancreas. They are also present in regions of the brain involved in reward and motivation, which is the same reason these drugs reduce food-related craving rather than only physically limiting intake.

If the same circuitry participates in alcohol reward, an effect on both is mechanistically coherent. Coherent is not the same as demonstrated, and the human evidence is what is summarised above.

Drinking On A GLP-1: Practical Considerations

Separate from any effect on craving, there are reasons alcohol behaves differently on these medications:

  • Less food in the stomach. Reduced intake and delayed gastric emptying change how alcohol is absorbed and how it feels.
  • Overlapping side effects. Nausea and reflux are among the most reported effects of this drug class, and alcohol aggravates both.
  • Calories without nutrition. When total intake is already limited, alcohol displaces the protein and micronutrients you have little room for.
  • Blood sugar. Relevant particularly for anyone also taking insulin or a sulfonylurea, where hypoglycaemia risk is real.
GI adverse events quantified across 106,395 trial participantsMeta-analysis of 55 RCTs
Systematic review and meta-analysis — Gastroenterology, 2025

Pooling 55 placebo-controlled randomised trials, GLP-1 receptor agonists increased cholelithiasis risk (RR 1.46, 95% CI 1.09–1.97) and probably increased GERD risk (RR 2.19, 95% CI 1.48–3.25). Gastrointestinal effects were the most frequently reported adverse events overall.

View study abstract ↗

Important: If you take insulin or a sulfonylurea alongside a GLP-1, alcohol raises hypoglycaemia risk. This is a conversation to have with your prescriber rather than something to work out yourself.

What This Evidence Is Not

GLP-1 medications are not approved for alcohol use disorder anywhere, and nothing here should be read as suggesting anyone seek one for that purpose. Effective, approved treatments for alcohol use disorder exist and are supported by far more evidence than nine weeks in 48 people.

If drinking is a problem, that is a conversation with a clinician about treatments that already have the evidence behind them.

GLP-1 Full Guide
The book

GLP-1 Full Guide

Everything on this page, and the other 39 articles, in one 151-page book — plus a 30-day protocol, four weeks of meal plans and the tracker pages, none of which are on the site.

19 peer-reviewed references, cited by PMID and DOI. Where two studies disagree, both are shown.

See the book →

FAQ

Do GLP-1 medications reduce alcohol consumption?

A 2025 randomised trial in 48 adults with alcohol use disorder found low-dose semaglutide significantly reduced drinks per drinking day and weekly craving over nine weeks. It is a real but early finding — small sample, short duration, low doses.

Can I drink alcohol on Ozempic or Wegovy?

There is no absolute prohibition, but alcohol aggravates nausea and reflux, which are among the most common effects of this drug class, and it adds calories when your total intake is already limited. Ask your prescriber about your situation.

Is alcohol dangerous with a GLP-1 medication?

The specific risk to raise with a clinician is hypoglycaemia, particularly if you also take insulin or a sulfonylurea. Alcohol also hits harder on an emptier stomach.

Are GLP-1 drugs approved to treat alcohol use disorder?

No. They are not approved for that indication anywhere. Approved treatments for alcohol use disorder exist and have far more evidence behind them.

Scientific References

  1. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025;82(4):395–405. PubMed PMID: 39937469.
  2. Gastrointestinal adverse events associated with GLP-1 receptor agonists: a systematic review and meta-analysis (55 RCTs, n=106,395). Gastroenterology, 2025. View abstract.
  3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183.

Medical Disclaimer

This article is educational and not medical advice, and does not recommend, endorse, or provide dosing guidance for any prescription medication. GLP-1 medications require a prescription and medical supervision. Talk to a qualified clinician before starting, stopping, or changing any medication.

The Iron Verdict

Get the evidence, not the hype

Free, independent breakdowns of GLP-1 research, supplement evidence and product picks — straight to your inbox. No spam, no paid rankings.

Free forever. Unsubscribe anytime. No spam, no paid rankings.